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Simple Summary: Although it has been suggested that cancer risk and genetic variation vary by
population, there is still a lack of research on non-European populations. In this study, we applied
Korean patients as a model to find out the way to conduct BRCA1/2-related clinical studies in non-
European populations who do not have as much clinical data as Europeans. The BRCA1/2 variants
were classified following the 2015 ACMG standards/guidelines and using a multifactorial probability-
based approach. To estimate the additional sample numbers needed to resolve BRCA1/2 unclassified
status, we applied a simulation analysis considering population-specific clinical characteristics. In
addition, we estimated the risks of breast or ovarian cancer for BRCA1/2 carriers by mutation
regions. Data from this study reveal that BRCA1/2 variants in the non-European population are
highly specific; therefore, population-specific study is essential for clinical application of treatment or
prevention for breast or ovarian cancer.
Abstract: In this study, we performed a comprehensive analysis of BRCA1/2 variants and associated
cancer risk in Korean patients considering two aspects: variants of uncertain significance (VUS)
and pathogenic or likely pathogenic variants (PLPVs) in BRCA1 and BRCA2. This study included
5433 Korean participants who were tested for BRCA1/2 genes. The BRCA1/2 variants were classified
following the standards/guidelines for interpretation of genetic variants and using a multifactorial
probability-based approach. In Korea, 15.8% of participants had BRCA1 or BRCA2 PLPVs. To estimate
the additional sample numbers needed to resolve unclassified status, we applied a simulation analysis.
The simulation study for VUS showed that the smaller the number of samples, the more the posterior
probability was affected by the prior probability; in addition, more samples for BRCA2 VUS than
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those of BRCA1 VUS were required to resolve the unclassified status, and the presence of clinical
information associated with their VUS was an important factor. The cumulative lifetime breast cancer
risk was 59.1% (95% CI: 44.1–73.6%) for BRCA1 and 58.3% (95% CI: 43.2–73.0%) for BRCA2 carriers.
The cumulative lifetime ovarian cancer risk was estimated to be 36.9% (95% CI: 23.4–53.9%) for
BRCA1 and 14.9% (95% CI: 7.4–28.5%) for BRCA2 carriers.
Keywords: BRCA1; BRCA2; breast cancer; ovarian cancer; variants of uncertain significance;
cumulative risk
1. Introduction
Familial breast–ovarian cancer associated with the BRCA1 (phenotype MIM #604370)
or BRCA2 (MIM #612555) is an autosomal dominant disorder that has been exceptionally
well-studied in terms of diagnosis, treatment, management, and prevention. Especially
as Poly (ADP-ribose) polymerase inhibitors have shown clinical benefit for treatment of
breast or ovarian cancer with the presence of a BRCA1 or BRCA2 pathogenic variant [1,2],
identifying these variants is more important than ever.
There are two approaches to classifying BRCA1 or BRCA2 genetic variants; one is
based on the 2015 American College of Medical Genetics and Genomics (ACMG) and
the Association for Molecular Pathology (AMP) standards and guidelines (briefly, 2015
ACMG/AMP) [3], and the other is based on a Bayesian framework set forth by the Interna-
tional Agency for Research on Cancer (IARC) recommendations [4,5]. Recently, the ClinGen
Sequence Variant Interpretation Working Group showed that the 2015 ACMG/AMP cri-
teria are compatible with Bayesian statistical reasoning [6]. To date, multiple databases
for BRCA1 or BRCA2 genetic variants have been developed [7–9]. However, most of the
data are based on European populations. Although it has been suggested that cancer
risk and genetic variation vary by populations [10–12], there is still a lack of research on
non-European populations.
When conducting BRCA1- or BRCA2-related studies in non-European populations
who do not currently have as much clinical data as Europeans, it is important to predict
how many samples are needed to resolve the inconclusive state of variants of uncertain
significance (VUS). In addition, as it has been suggested that there are distinct differ-
ences in clinical characteristics of breast or ovarian cancer [13–15] and in the spectrum of
BRCA1/2 variants between non-Europeans and Europeans [10,11,16,17], questions arise
about whether the cancer risk by pathogenic or likely pathogenic variants (PLPVs) in
BRCA1/2 estimated based on Europeans can be used in non-European populations. Here,
we performed a comprehensive analysis for BRCA1/2 variants and associated cancer risk
in Korean patients with respect to VUS and PLPVs in BRCA1 and BRCA2.
2. Results
2.1. Participant Characteristics
The Korea ONCOgene Research and Diagnosis (KONCORD) consortium was formed
for the purposes of this study. The KONCORD consortium consists of eight major clin-
ical genetics laboratories at university hospitals and commercial genetic laboratories in
Korea. The data from KONCORD and a previous cohort [18] were collected. There were
5433 participants enrolled in this study. Demographics of study participants are described
in Table S1. In our study cohort, the mean age of diagnosis was 43.5 years (range 19–82,
95% CI: 43.1–43.8 years), and 33.5% of participants had a family history of cancer. Patients
with unilateral breast cancer (58.6%) were most frequently enrolled, followed by patients
with ovarian cancer (7.4%), bilateral breast cancer (6.4%), and both breast and ovarian
cancer (1.3%). The pathologic subtypes of breast or ovarian cancer enrolled are described
in Table S2.
Cancers 2021, 13, 2192 3 of 15
2.2. Classification of Genetic Variants in BRCA1 or BRCA2 Genes Following 2015 ACMG/AMP
and IARC Criteria
We present the entire analysis workflow in Figure 1. Of the 5433 cases, 15.1% (95% CI:
14.1–16.2%) of participants had BRCA1 or BRCA2 PLPVs in the initial analysis; the 125 PLPVs
in BRCA1 were detected in 459 participants (8.4%, 95% CI: 7.7–9.3%), the 111 PLPVs in
BRCA2 were detected in 361 participants (6.6%, 95% CI: 6.0–7.4%), and 2 participants had
both BRCA1 and BRCA2 PLPVs (both c.5030_5033del (p.Thr1677Ilefs*2) in BRCA1 and
c.1399A>T (p.Lys467*) in BRCA2 were detected in one bilateral breast cancer patient, and
both c.5496_5506delinsA (p.Val1833Serfs*7) in BRCA1 and c.7480C>T (p.Arg2494*) in BRCA2
were detected in another bilateral breast cancer patient) (Tables S3 and S4).




Figure 1. Analysis workflow in this study. A comprehensive analysis of BRCA1/2 variants and 
associated cancer risk in Korean patients, considering two aspects: variants of uncertain signifi-
cance (VUS) and pathogenic or likely pathogenic variants (PLPVs) in BRCA1 and BRCA2. The 
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) was accessed on 17 March 2020 and gnomAD 
(https://gnomad.broadinstitute.org/) was accessed on 13 March 2020. 2015 ACMG/AMP, 2015 
American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular 
Pathology (AMP); BRCA1/2+, carriers of BRCA1 or BRCA2 (likely) pathogenic variants; IARC, 
International Agency for Research on Cancer; P/LP, pathogenic or likely pathogenic variants. 
2.3. Simulation Study on the Estimation of Additional Sample Numbers for Resolving 
Unclassified Status 
Many genetic variants are unclassified due to insufficient evidence. For these, we es-
timated how many cases would be needed to resolve this unclassified status using a sim-
ulation study based on the multifactorial likelihood model. If a BRCA1 variant was genu-
inely benign but was unclassified at the time of analysis, only one case with this same 
variant would be needed to be classified as (likely) benign with a 0.049 or less posterior 
probability at a prior probability of 0.02–0.03, 5 cases at 0.26–0.29, 7 cases at 0.66, 10 cases 
at 0.81, and 12 cases at 0.96 (Figure 2a, Table S8). If an unclassified BRCA1 variant was 
genuinely pathogenic, 9 cases with this variant would be required to reach (likely) patho-
genic class (with 0.95 or more posterior probability) at a prior probability 0.02–0.03, 7 cases 
at 0.26, 6 cases at 0.29, 4 cases at 0.66, 3 cases at 0.81, and 1 case at 0.96 (Figure 2b, Table 
S8). 
If an unclassified BRCA2 variant was really benign, 1 case at a prior probability of 0.02–
0.03, 20 cases at 0.26, 21 cases at 0.29, 31 cases at 0.66, 36 cases at 0.81, and 44 cases at 0.96 would 
be needed to downgrade this to a (likely) benign variant (Figure 2c, Table S9). If the BRCA2 
VUS was actually pathogenic, 28 cases at a prior probability of 0.02–0.03, 20 cases at 0.26, 19 
cases at 0.29, 12 cases at 0.66, 9 cases at 0.81, and only 1 case at 0.96 would be needed to upgrade 
this variant to a (likely) pathogenic variant (Figure 2d, Table S9). 
Figure 1. Analysis workflow in this study. A comprehensive analysis of BRCA1/2 variants and associated cancer risk in
Korean patients, considering two aspects: variants of u certai significance (VUS) and pathogenic or likely pathogenic
variants (PLPVs) in BRCA1 and BRCA2. The ClinVar ( ttps://www.ncbi.nlm.nih.gov/clinvar/) was accessed on 17 March
2020 and gnomAD ( tt s: /gnomad.broadinstitute.org/) was accessed on 13 arc 2020. 2015 ACMG/AMP, 2015
American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP);
BRCA1/2+, carriers of BRCA1 or BRCA2 (likely) pathogenic variants; IARC, International Agency for Research on Cancer;
P/LP, pathogenic or likely pathogenic variants.
For the combined likelihood ratio (LR), we compared personal/family cancer his-
tory between the pathogenic (349 cases in BRCA1+, 291 cases in BRCA2+) and benign
(2931 cases) groups (Table S5). For pathologic profiles, the BRCA1+ group had a signif-
icantly increased likelihood of basal-like subtype breast cancer grade 2 (LR = 4.7, 95%
CI: 3.0–7.2) or 3 (LR = 4.6, 95% CI: 3.9–5.5) or high-grade ovarian cancer (LR = 3.4, 95%
CI: 2.6–7.5), while the BRCA2+ gr up had a significantly increased likelihood of luminal
s btype breast cancer grad s 2 (LR = 1.2, 95% CI: 1.02–1.4) and 3 (LR = 1.5, 95% CI: 1.1–1.9).
Of 44 differ nt VUS in BRCA1, 16 (36.4%) were not submitted to ClinVar (accessed
Ma ch 2020), while 26 (24.8%) of 105 BRCA2 VUS were not (Tables S6 and S7). In addition,
of th BRCA1 VUS, 39% were not located in functional domains, 37% were located in
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BRCA1 C Terminus domain (BRCT), 22% in Ring finger domain, and 2% in Serine-rich
domain associated with BRCT (by Pfam (http://pfam.xfam.org/ [accessed on 18 April
2021])). Of the BRCA2 VUS, only 27% were located in functional domains, 10% in the
BRCA2 repeat region, 7% in BRCA2 helical, 5% in oligonucleotide/oligosaccharide-binding,
domain 1 (OB1), and 2% in oligonucleotide/oligosaccharide-binding, domain 3 (OB3).
The IARC classification of VUS in BRCA1 or BRCA2 was analyzed using multifactorial
probability. Of 44 different VUS in BRCA1, 9 variants were IARC class 1, 16 variants
were class 2, 14 variants were class 3, one variant was class 4, and four variants were
class 5. Analysis of the 105 different VUS in BRCA2 indicated that 11 were class 1, 76 were
class 2, and 18 were class 3. When we considered the rationale by a previous study that
posterior probabilities for any variants with a combined LR between 0.5 and 2 were not
calculated [19], the combined LR of any VUS in BRCA1 was not included in the range, and
the combined LR of 58 out of 105 VUS in BRCA2 were included. Considering the rationale
by a previous study [19], the posterior probabilities of only 47 VUS in BRCA2 could be
calculated: there were 11 class 1 VUS, 28 class 2 VUS, and 8 class 3 VUS.
Finally, considering the recommendations by the previous study [20], 15.8% (858 out
of 5433, 95% CI: 14.8–16.9%) of participants had BRCA1 or BRCA2 PLPVs in our cohort;
the 130 PLPVs in BRCA1 were detected in 495 participants (9.1%, 95% CI: 8.3–10.0%),
the 111 PLPVs in BRCA2 were detected in 361 participants (6.6%, 95% CI: 6.0–7.4%), and
2 participants had both BRCA1 and BRCA2 PLPVs.
2.3. Simulation Study on the Estimation of Additional Sample Numbers for Resolving
Unclassified Status
Many genetic variants are unclassified due to insufficient evidence. For these, we
estimated how many cases would be needed to resolve this unclassified status using a
simulation study based on the multifactorial likelihood model. If a BRCA1 variant was
genuinely benign but was unclassified at the time of analysis, only one case with this
same variant would be needed to be classified as (likely) benign with a 0.049 or less
posterior probability at a prior probability of 0.02–0.03, 5 cases at 0.26–0.29, 7 cases at 0.66,
10 cases at 0.81, and 12 cases at 0.96 (Figure 2a, Table S8). If an unclassified BRCA1 variant
was genuinely pathogenic, 9 cases with this variant would be required to reach (likely)
pathogenic class (with 0.95 or more posterior probability) at a prior probability 0.02–0.03,
7 cases at 0.26, 6 cases at 0.29, 4 cases at 0.66, 3 cases at 0.81, and 1 case at 0.96 (Figure 2b,
Table S8).
If an unclassified BRCA2 variant was really benign, 1 case at a prior probability of
0.02–0.03, 20 cases at 0.26, 21 cases at 0.29, 31 cases at 0.66, 36 cases at 0.81, and 44 cases at
0.96 would be needed to downgrade this to a (likely) benign variant (Figure 2c, Table S9).
If the BRCA2 VUS was actually pathogenic, 28 cases at a prior probability of 0.02–0.03,
20 cases at 0.26, 19 cases at 0.29, 12 cases at 0.66, 9 cases at 0.81, and only 1 case at 0.96 would
be needed to upgrade this variant to a (likely) pathogenic variant (Figure 2d, Table S9).
We then estimated how much the posterior probability is affected by whether or
not clinical information such as pathologic profiles or personal/family cancer history
exists, with specific focus on BRCA2, c.7522G>A, p.(Gly2508Ser) (Figure 2e, Table S10)
and BRCA1, c.5339T>C, p.(Leu1780Pro) (Figure 2f, Supplementary Table S11). The prior
probability of these two variants was the same at 0.66, and these were both classified as VUS
in our previous study [18]. However, by registering more cases with these two variants
in the current study, the BRCA2, c.7522G>A, p.(Gly2508Ser) variant was downgraded
from IARC 3 (total 1 case, posterior probability 0.562) to IARC 2 (total 11 cases, posterior
probability 0.047), while the BRCA1, c.5339T>C, p.(Leu1780Pro) variant was upgraded
from IARC 3 (total 4 cases, posterior probability 0.652) to IARC 5 (total 26 cases, posterior
probability 1).
In the case of the BRCA2, c.7522G>A, p.(Gly2508Ser) variant, using simulation analysis,
if the missing rate was 0%, the posterior probability in 1 case was estimated to be 0.577,
and posterior probability went down to 0.135 when the total number of samples reached 11.
However, if missing rate was up to 75%, the posterior probability was 0.659 in 1 case, and
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even when 11 cases were accumulated, the posterior probability was barely lowered (0.640).
In the case of BRCA1 c.5339T>C, p.(Leu1780Pro), if the missing rate was 0%, the posterior
probability in one case was 0.764, and it went up to 0.999 when there were 26 sample
cases; however, if the missing rate was up to 75%, the posterior probability in 26 cases
was predicted to be 0.952. With this simulation study of the BRCA1 c.5339T>C variant, we
could estimate the number of cases required to upgrade from IARC 3 to IARC 4 depending
on the missing rate. If the missing rate was 0%, 7 cases (posterior probability 0.959) were
required, while 9 cases were required at a missing rate of 25%, 13 cases were required at a
missing rate of 50%, and 26 cases were required at a missing rate of 75%.




Figure 2. Simulation study estimating the sample numbers required to resolve unclassified status. 
We created two benign and pathogenic datasets, independent from the benign and pathogenic 
model groups. The benign set contained samples that had only (likely) benign variants according 
to the 2015 ACMG/AMP or IARC 1/2 variants, while the pathologic set contained samples that had 
(likely) pathogenic variants or IARC 4/5 variants. A simulation study on the posterior probability 
in (a) BRCA1 benign model group, (b) BRCA1 pathogenic model group, (c) BRCA2 benign model 
group, and (d) BRCA2 benign model group. Simulation study on the posterior probability depend-
ing on the presence of clinical information (e) at c.7522G>A, p.(Gly2508Ser) in BRCA2 and (f) 
c.5339T>C, p.(Leu1780Pro) in BRCA1. The prior probability of these two variants was the same at 
0.66. 
We then estimated how much the posterior probability is affected by whether or not clin-
ical information such as pathologic profiles or personal/family cancer history exists, with spe-
cific focus on BRCA2, c.7522G>A, p.(Gly2508Ser) (Figure 2e, Table S10) and BRCA1, 
c.5339T>C, p.(Leu1780Pro) (Figure 2f, Supplementary Table S11). The prior probability of 
these two variants was the same at 0.66, and these were both classified as VUS in our 
previous study [18]. However, by registering more cases with these two variants in the 
current study, the BRCA2, c.7522G>A, p.(Gly2508Ser) variant was downgraded from 
IARC 3 (total 1 case, posterior probability 0.562) to IARC 2 (total 11 cases, posterior prob-
ability 0.047), while the BRCA1, c.5339T>C, p.(Leu1780Pro) variant was upgraded from 
IARC 3 (total 4 cases, posterior probability 0.652) to IARC 5 (total 26 cases, posterior prob-
ability 1). 
Figure 2. Simulation study estimating the sample numbers r q ired to solv unclassified statu . W cre ed two benign
and pathogenic datasets, independe t from the benign and pathogenic model groups. The benign set contained samples
that had only (likely) benign variants according to the 2015 ACMG/AMP or IARC 1/2 variants, while the pathologic
set contained samples that had (likely) pathogenic variants or IARC 4/5 variants. A simulation study on the posterior
probability in (a) BRCA1 benign model group, (b) BRCA1 pathogenic model group, (c) BRCA2 benign model group, and
(d) BRCA2 benign model group. Simulation study on the posterior probability depending on the presence of clinical
information (e) at c.7522G>A, p.(Gly2508Ser) in BRCA2 and (f) c.5339T>C, p.(Leu1780Pro) in BRCA1. The prior probability
of these two variants was the same at 0.66.
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2.4. Analysis of BRCA1/2 PLPVs in the Korean BRCA
In the Korean general population in gnomAD (non-cancer, v.2.1.1, 1887 subjects),
5 different BRCA1 PLPVs in 7 carriers and 6 different BRCA2 PLPVs in 7 carriers were found.
Finally, there were 130 different BRCA1 PLPVs and 112 BRCA2 PLPVs in the Korean BRCA.
In BRCA1, c.81-9C>G, c.390C>A (p.(Tyr130*)), c.2433del (p.(Lys812Argfs*3)), c.3627dup
(p.(Glu1210Argfs*9)), c.5339T>C (p.(Leu1780Pro)), and c.5445G>A (p.(Trp1815*)) were
found only in the Korean population in gnomAD (v.2.1.1), while c.1399A>T (p.(Lys467*))
and c.3744_3747del (p.(Ser1248Argfs*10)) in BRCA2 were found only in the Korean and not
in other populations in gnomAD.
We searched for the population in the gnomAD that showed the maximum allele
frequency at individual PLPVs found in the Korean BRCA. Most BRCA1 (83.1%, 108/130)
or BRCA2 (77.7%, 87/112) PLPVs found in the Korean BRCA were absent in gnomAD,
followed by Korean (4.6%, 6/130), European (Finnish or non-Finnish) (3.8%, 5/130) or other
populations (South Asian, Latino, or other, 3.8%, 5/130), and East Asian (except Korean,
2.3%, 3/130) in BRCA1 (Figure 3a), while followed by other populations (African/African
American, Latino, Ashkenazi Jewish, or South Asian, 9.8%, 11/112), European (7.1%,
8/112), Korean (4.5%, 5/112), and East Asian (0.9%, 1/112) in BRCA2 (Figure 4a).




Figure 3. Analysis of pathogenic or likely pathogenic variants in BRCA1. (a) Distribution of pathogenic or likely pathogenic 
variants (PLPVs) in BRCA1 in the Korean BRCA cohort. The population in gnomAD with maximum allele frequency at 
individual PLPVs is marked in each color in the circle of lollipop. (b) Comparative analysis of the proportion of BRCA1 
PLPVs found in every mutation bin between the Korean BRCA and a large-scale cohort including various ethnicities over 
6 continents. The 30 mutation bins across the span of the coding DNA sequence of BRCA1 were constructed using an 
algorithm in which each mutation bin contained approximately equal numbers of BRCA1 PLPVs in a previous study [21]. 
(c) Estimation of cumulative risks of breast and ovarian cancers for BRCA1 carriers by mutation region: region 1 (5′to 
c.2281, breast cancer cluster regions (BCCR)), region 2 (c.2282 to c.4071, ovarian cancer cluster regions (OCCR)), and region 
3 (c.4072 to 3′, BCCR) [21,22]. RING, RING finger domain (24–64) by Pfam (http://pfam.xfam.org/ (accessed on 1 March 
2021)); Serine-rich, serine-rich domain associated with BRCT (344–508); BRCT, BRCA1 C Terminus domain (1662–1723, 
1756–1842); P/LP, pathogenic or likely pathogenic variants; BC, breast cancer; OC, ovarian cancer. 
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6 continents. The 30 mutation bins across the span of the coding DNA sequence of BRCA1 were constructed using an
algorithm in which each mutation bin contained approximately equal numbers of BRCA1 PLPVs in a previous study [21].
(c) Estimation of cumulative risks of breast and ovarian cancers for BRCA1 carriers by mutation region: region 1 (5′ to
c.2281, breast cancer cluster regions (BCCR)), region 2 (c.2282 to c.4071, ovarian cancer cluster regions (OCCR)), and region
3 (c.4072 to 3′, BCCR) [21,22]. RING, RING finger domain (24–64) by Pfam (http://pfam.xfam.org/ (accessed on 1 March
2021)); Serine-rich, serine-rich domain associated with BRCT (344–508); BRCT, BRCA1 C Terminus domain (1662–1723,
1756–1842); P/LP, pathogenic or likely pathogenic variants; BC, breast cancer; OC, ovarian cancer.




Figure 4. Analysis of pathogenic or likely pathogenic variants in BRCA2. (a) Distribution of pathogenic or likely pathogenic 
variants (PLPVs) in BRCA2 in the Korean BRCA cohort. (b) Comparative analysis of the proportion of BRCA2 PLPVs 
found in every mutation bin between the Korean BRCA and large-scale cohort. The 19 mutation bins across the span of 
the coding DNA sequence of BRCA2 were constructed using an algorithm in which each mutation bin contained approx-
imately equal numbers of BRCA2 PLPVs in a previous study [21]. (c) Estimation of cumulative risks of breast and ovarian 
cancers for BRCA2 carriers by mutation regions: region 1 (5′ to c.2830, breast cancer cluster regions (BCCR)), region 2 
(c.2831 to c.6401, ovarian cancer cluster regions (OCCR)), and region 3 (c.6402 to 3′, BCCR) [21,22]. R, BRCA2 repeat (1002–
1035, 1213–1245, 1422–1454, 1518–1550, 1665–1696, 1838–1869, 1973–2004, 2052–2084) by Pfam (http://pfam.xfam.org/ (ac-
cessed on 1 March 2021)); Helical, BRCA2 helical (2481–2667); OB1, oligonucleotide/oligosaccharide-binding, domain 1 
(2670–2796); T, Tower (2831–2872); OB3, oligonucleotide/oligosaccharide-binding, domain 3 (3052–3186); P/LP, pathogenic 
or likely pathogenic variants; BC, breast cancer; OC, ovarian cancer. 
2.5. Estimating the Risks of Breast and Ovarian Cancers in BRCA1 and BRCA2 Carriers 
Our estimates of breast and ovarian cancer risk for BRCA1 or BRCA2 carriers are shown 
in Figures 3c and 4c, respectively. The cumulative lifetime risk of breast cancer for BRCA1 
carriers was 59.1% (95% CI: 44.1–73.6%): 64.4% (95% CI: 37.8–87.1%) in region 1 (~c.2281, 
BCCR), 43.4% (95% CI: 22.4–69.8%) in region 2 (c.2282 to c.4071, OCCR), and 67.3% (95% CI: 
41.1–88.3%) in region 3 (c.4072~, BCCR) (Figure 3c, Supplementary Table S13). The lifetime 
cumulative risk of ovarian cancer for BRCA1 carriers was estimated to be 36.9% (95% CI: 23.4–
53.9%): 39.7% (95% CI: 16.6–72.8%) in region 1, 28.1% (95% CI: 12.1–55.8%) in region 2, and 
44.4% (95% CI: 19.9–76.0%) in region 3 (Figure 3c, Supplementary Table S13). The lifetime 
cumulative risk of breast cancer for BRCA2 carriers was similar to that of BRCA1. It was 
58.3% (95% CI: 43.2–73.0%), and there were also differences in the risk by region: 76.1% 
(95% CI: 42.8–96.0%) in region 1 (~c.2830, BCCR), 43.4% (95% CI: 22.4–69.8%) in region 2 
(c.2831 to c.6401, OCCR), and 60.0% (95% CI: 37.5–81.1%) in region 3 (c.6402~, BCCR) (Fig-
ure 4c, Supplementary Table S14). The lifetime cumulative risk of ovarian cancer for 
BRCA2 carriers was 14.9% (95% CI: 7.4–28.5%): 15.8% (95% CI: 2.4–70.7%) in region 1, 8.6% 
(95% CI: 2.3–28.6%) in region 2, and 20.0% (95% CI: 7.5–46.4%) in region 3 (Figure 4c, Sup-
plementary Table S14). 
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(PLPVs) in BRCA2 in the Korean BRCA cohort. (b) Comparative analysis of the proportion of BRCA2 PLPVs found
in every mutation bin between the Korean BRCA and large-sca e cohort. The 19 mutation bins across the span of the coding
DNA sequence of BRCA2 were constructed using an algorithm in which each mutation bin contained approximately equal
numbers of BRCA2 PLPVs in a previous study [21]. (c) Estimation of cumulative risks of breast and ovarian cancers for
BRCA2 carriers by mutation regions: region 1 (5′ to c.2830, breast cancer cluster regions (BCCR)), region 2 (c.2831 to c.6401,
ovarian cancer cluster regions (OCCR)), and region 3 (c.6402 to 3′, BCCR) [21,22]. R, BRCA2 repeat (1002–1035, 1213–1245,
1422–1454, 1518–1550, 1665–1696, 1838–1869, 1973–2004, 2052–2084) by Pfam (http://pfam.xfam.org/ (accessed on 1 March
2021)); Helical, BRCA2 helical (2481–2667); OB1, oligonucleotide/oligosaccharide-binding, domain 1 (2670–2796); T, Tower
(2831–2872); OB3, oligonucleotide/oligosaccharide-binding, domain 3 (3052–3186); P/LP, pathogenic or likely pathogenic
variants; BC, breast cancer; OC, ovarian cancer.
Compared with the proportion of BRCA1/2 PLPVs in a large-scale cohort including
various ethnicities [21], the BRCA1 PLPVs in mutation bins 5, 6, 10, 18, 19, 22, 27, and 30
(Figure 3b) and the BRCA2 PLPVs in mutation bins 3, 9, 15, and 18 (Figure 4b) found in the
Korean BRCA showed statistically increased likelihood ratios (Table S12).
2.5. Estimating the Risks of Breast and Ovarian Cancers in BRCA1 and BRCA2 Carriers
Our estimates of breast and ovarian cancer risk for BRCA1 or BRCA2 carriers are
shown in Figures 3c and 4c, respectively. The cumulative lifetime risk of breast cancer for
BRCA1 carriers was 59.1% (95% CI: 44.1–73.6%): 64.4% (95% CI: 37.8–87.1%) in region 1
(~c.2281, BCCR), 43.4% (95% CI: 22.4–69.8%) in region 2 (c.2282 to c.4071, OCCR), and 67.3%
(95% CI: 41.1–88.3%) in region 3 (c.4072~, BCCR) (Figure 3c, Supplementary Table S13). The
lifetime cumulative risk of ovarian cancer for BRCA1 carriers was estimated to be 36.9%
(95% CI: 23.4–53.9%): 39.7% (95% CI: 16.6–72.8%) in region 1, 28.1% (95% CI: 12.1–55.8%) in
region 2, and 44.4% (95% CI: 19.9–76.0%) in region 3 (Figure 3c, Supplementary Table S13).
The lifetime cumulative risk of breast cancer for BRCA2 carriers was similar to that of
BRCA1. It was 58.3% (95% CI: 43.2–73.0 ), and there were also differences in the risk by
region: 76.1% (95% CI: 42.8–96.0%) in region 1 (~c.2830, BCCR), 43.4% (95% CI: 22.4–69.8%)
in region 2 (c.2831 to c.6401, OCCR), and 60.0% (95% CI: 37.5–81.1%) in region 3 (c.6402~,
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BCCR) (Figure 4c, Supplementary Table S14). The lifetime cumulative risk of ovarian
cancer for BRCA2 carriers was 14.9% (95% CI: 7.4–28.5%): 15.8% (95% CI: 2.4–70.7%) in
region 1, 8.6% (95% CI: 2.3–28.6%) in region 2, and 20.0% (95% CI: 7.5–46.4%) in region 3
(Figure 4c, Supplementary Table S14).
3. Discussion
In the present study, our major question was how causative BRCA1 or BRCA2 variants
in non-European populations differ from those in European populations, which are most
studied. Another question was how different were the clinical outcomes caused by their
variants. We considered BRCA1/2 VUS and PLPVs in this study.
The BRCA1/2 VUS has been investigated in the European population with large-
scale research based on clinical information associated with BRCA1/2 [8,23–25]. These
efforts have made it possible for recurrent VUS detected in European population to be
reclassified as pathogenic or benign variants. In particular, an IARC classification for
BRCA1 and BRCA2 using a multifactorial likelihood model has made a great contribution
to reclassifying VUS into (likely) benign or (likely) pathogenic variants. Recently, a large-
scale multifactorial likelihood analysis for BRCA1 and BRCA2 was applied by Evidence-
based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) [8]. When
this multifactorial probability-based model is applied, integral analyses such as personal
or family history, pathologic profiles, or segregation LRs are needed. However, to date,
these LRs are estimated based on the clinical characteristics of the European population.
These are limitations to applying such LRs in non-European populations. To overcome
these limitations, although there was a limit to the study of small numbers, we previously
estimated the LRs of personal and family history, pathologic profiles, and co-occurrence
with pathogenic variants in Korean patients with breast cancer [18].
In this study, data from our previous study was extended and also included Korean
ovarian cancer. Interestingly, we found that some of the BRCA1 or BRCA2 VUS reported
in the previous study changed their variant classes to (likely) benign variants, with two
gold stars of review status in ClinVar (accessed on 17 March 2020). In the two cases
(c.7522G>A, p.(Gly2508Ser) in BRCA2 and 5339T>C, p.(Leu1780Pro) in BRCA1) where the
prior probability (0.66) was the same and posterior probability was similar in the previous
study, posterior probability and their classification have completely changed as clinical
cases with these variants accumulated. The c.7522G>A, p.(Gly2508Ser) in BRCA2 went
from IARC 3 (total 1 case, posterior probability 0.562) to IARC 2 (total 11 cases, posterior
probability 0.047), and c.5339T>C, p.(Leu1780Pro) in BRCA1 went from IARC 3 (total
4 cases, posterior probability 0.652) to IARC 5 (total 26 cases, posterior probability 1).
After our study, the 5339T>C, p.(Leu1780Pro) in BRCA1 was revealed as a Korean founder
pathogenic variant [26,27].
In particular, clinical genetic laboratories should provide genetic test reports by con-
ducting clinical interpretations of genetic variants with genetic testing within a specified
turnaround time. Therefore, whenever a very rare variant is detected, there is a limit
to conducting a functional study for it. In this respect, the variant classification using a
multifactorial likelihood model that does not require functional research can be useful. The
KONCORD consortium is a network consisting of clinical genetic laboratories that, when a
rare variant is detected, is configured to quickly collect cases with the same corresponding
variant detected, using the network to perform an integrated analysis. Therefore, to take
full advantage of this network, it is important to predict how many samples can solve the
unclassified status when collected, along with to recognize the limitations of using the
multifactorial likelihood model.
For these, we applied a simulation analysis for BRCA1/2 VUS. The smaller the number
of samples, the more the posterior probability is affected by prior probability, the more
samples for BRCA2 VUS are needed to resolve unclassified status compared with BRCA1
VUS, and the presence of clinical information associated with VUS is an important factor.
First, prior probability is important when there are a small number of samples. For example,
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the posterior probability of c.5017_5019del, p.(His1673del) in BRCA1 (total 5 cases, com-
bined LR 146.848019) in our study was 0.999716 (class 5, pathogenic), while the posterior
probability of this variant (total 9 cases, combined LR 29.735396) in the ENIGMA study [8]
was estimated to be 0.479072 (class 3, uncertain significance). The most important cause of
this difference was a different prior probability applied in these two studies: we applied
a 0.96 prior probability for this variant using the VEST-indel algorithm (CRVAT), while a
0.03 prior probability was applied in the ENIGMA study because Align-GVGD does not
score in-frame indels; therefore, the highest Align-GVGD priority of the deleted based was
applied. The predictions of pathogenicity for indel variants are not as well established as
those for single nucleotide variants. We checked the prediction results of pathogenicity for
this variant using other in silico tools: damaging with confidence score 0.894 by SIFT indel,
neutral with−2.168 score by PROVEAN. In the previous study, the accuracy of any in silico
prediction for indels did not reach >90% [28]. If the prior probability of c.5017_5019del,
p.(His1673del) in BRCA1 in this study is greater than 0.115, this variant could be classified
as (likely) pathogenic (posterior probability > 0.95) because the combined LR is 146.848019.
In addition, there were several VUS cases where the value of the prior probability was
not consistent with the functional impact result by known functional assays: c.5131A>G
(p.Lys1711Glu), c.5137G>T (p.Val1713Leu), c.5254G>A (p.Ala1752Thr), and c.5365G>C
(p.Ala1789Pro) in BRCA1; c.8702G>A (p.Gly2901Asp), c.9275A>G (p.Tyr3092Cys), and
c.9367A>G (p.Ser3123Gly) in BRCA2 (Supplementary Tables S6 and S7). Therefore, there is
a limit to the accuracy of the prior probability; so, if the number of samples is small, care
should be taken when analyzing the variants using the multifactorial likelihood model.
With simulation study, we could predict that an additional minimum of 12 cases
with the same variants in BRCA1 would be needed to classify these as (likely) benign
without relying on the prior probability; an additional minimum of 9 clinical cases with
same variants in BRCA1 would be required to reclassify variants as (likely) pathogenic.
An additional minimum of 44 clinical cases with the same variants in BRCA2 would be
required to reclassify variants as (likely) benign, and 28 cases would be required to reclassify
variants as (likely) pathogenic in BRCA2. To resolve unclassified status, more samples
are needed for BRCA2 VUS than BRCA1 VUS. This is caused by a difference in the range
of estimated combined LRs of real pathogenic variants between BRCA1 and BRCA2. In
addition, the combined LRs of all VUS in BRCA1 were <0.5 or >2, while only 44.8% (47/105)
VUS in BRCA2 had an LR within that range in this study. The lack of clinical information
associated with related VUS might lead to a greater difference in the posterior probability
results of VUS between BRCA1 and BRCA2. For better resolution of this indeterminate
status in BRCA2, other clinical factors that highlight the differentiation between pathogenic
and neutral status should be included in the multifactorial likelihood analysis.
Based on current cancer statistics in the USA (https://seer.cancer.gov/csr/1975_2017/
(accessed on 5 February 2021), including multiple ethnicities), 12.9% of women will develop
breast cancer and 1.2% of women will develop ovarian cancer during their lifetime. In
Korea, the breast and ovarian cancer risk in the general population is 6.4% and 0.97%,
respectively, based on our analysis derived from the annual report of cancer statistics in
Korea (https://ncc.re.kr/main.ncc?uri=english/sub04_Statistics (accessed on 15 October
2020) (Tables S13 and S14). The previous study based on the data from the Consortium of
Investigators of Modifiers of BRCA1/2 (CIMBA) has identified that there was a substantial
difference in variant type, frequency, and location by geographical region and race or
ethnicity [10]. In addition, over 50% of Asian BRCA variants were Asian-specific, and even
among Asian populations (Indian, Chinese, Korean, and Japanese populations) there were
significant differences [11]. For these reasons, we assumed that the patterns and effects of
BRCA1 or BRCA2 pathogenic variants related to breast or ovarian cancer in Korean are
different than those of other populations (not only non-Europeans but also other Asians).
In the current study, we found that there were regions of pathogenic variants in
BRCA1 or BRCA2 specially enriched in the Korean population (the BRCA1 PLPVs in
mutation bins 5, 6, 10, 18, 19, 22, 27, and 30 and the BRCA2 PLPVs in mutation bins 3, 9,
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15, and 18). Although there was a higher risk of breast or ovarian cancer in other general
populations compared with the Korean general population (in particular, the other general
populations have double the risk of breast cancer), the cumulative risks of breast or ovarian
cancer for Korean BRCA1 or BRCA2 carriers were comparable with those of European
carriers [22,29–36] (Tables S15 and S16). Therefore, in the population-based studies, the
odds ratios for breast cancer are higher in Asian than in European populations when
comparing case patients with controls: odds ratio 9.33 (95% CI: 7.00–12.43) for BRCA1
(protein-truncating variants) in Europeans, odds ratio 22.07 (95% CI: 6.91–70.48) for BRCA1
in Asians, odds ratio 5.38 (95% CI: 4.38–6.59) for BRCA2 in Europeans, and odds ratio 8.16
(95% CI: 4.90–13.57) for BRCA2 in Asians in the Breast Cancer Association Consortium’s
study [31]; odds ratio 29.06 (95% CI: 11.98–70.51) for BRCA1 (protein-truncating variants)
in Koreans, odds ratio 23.77 (95% CI: 10.57–53.50) for BRCA2 in Koreans in this study
(Table S15). Interestingly, the cumulative risks of breast or ovarian cancer for Korean
BRCA1 or BRCA2 carriers by region of BCCR or OCCR showed a different trend than what
was previously reported [22] (Tables S15 and S16). The cumulative risks for both breast
and ovarian cancer at OCCR were not higher than those at the other two BCCRs for both
Korean BRCA1 and BRCA2 carriers. However, since the number of samples in this study
was not as large as in the previous study [22], further research is required to verify them.
4. Materials and Methods
4.1. Participants
All centers of the KONCORD consortium obtained written informed consent from
participants, and local institutional review boards approved this study protocol. Study eli-
gibility criteria included Korean subjects (aged ≥18 years) who underwent whole BRCA1
or BRCA2 gene testing due to suspicion of high risk of familial breast–ovarian cancer.
Clinical data including sex, age, cancer site, onset age, family history of cancer, and labo-
ratory data including BRCA1/2 genetic testing results and histologic diagnosis (including
immunohistochemical stain results) were collected in this study.
4.2. Initial Classification of BRCA1 and BRCA2 Variants
Initially, we classified pathogenic, likely pathogenic, likely benign, and benign variants
considering 2015 ACMG/AMP criteria [3] or variant classification with review status in
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/, accessed on 17 March 2020). The BRCA1
and BRCA2 variants were analyzed based on NM_007294.3 (between c.1 and c.5563 region)
and NM_000059.3 (between c.1 and c.9925), respectively. Loss-of-function variants in
BRCA1 or BRCA2 genes are responsible for the development of a hereditary breast–ovarian
cancer syndrome [37]. Therefore, the pathogenic or likely pathogenic variants (PLPVs)
included null variants such as stop-gain, splice site disrupting, frameshift, or initiation
codon variants and other PLPVs according to the 2015 ACMG/AMP criteria. Variants with
≥5% allele frequency (BA1) in gnomAD (https://gnomad.broadinstitute.org/ (accessed
on 13 March 2020)) and other (likely) benign variants according to 2015 ACMG/AMP were
classified as (likely) benign variants. The remainder, including VUS with ≥two gold stars
of review status in ClinVar, or any variants with <two gold stars of review status in ClinVar,
were classified as VUS.
4.3. IARC Classification of Variants of Uncertain Significance
The IARC classification of VUS (which is the multifactorial probability of a VUS
being pathogenic) is based on Bayes theorem using the prior probability of causality and
combined likelihood ratio [24]. For the combined LR, we created a benign and pathogenic
(BRCA1/2+) group. The benign group included individuals with only (likely) benign
variants in BRCA1 or BRCA2, while the pathogenic group included BRCA1 PLPV carriers
(BRCA1+) and BRCA2 PLPV carriers (BRCA2+).
We considered LRs for personal/family cancer history, pathologic profiles, and co-
occurrence with pathogenic variants between benign and pathogenic groups following our
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previous study [18]. Briefly, 20 categories were used in the interval LR of personal/family
cancer history as follows: cancer type (unilateral breast cancer, bilateral breast cancer,
breast and ovarian cancer, ovarian cancer), age at diagnosis of cancer (<40 or ≥40 years in
unilateral breast cancer, <45 or ≥45 years in bilateral breast cancer), and number of family
members with breast, ovarian, prostate, or pancreatic cancer (0, 1, 2, and ≥3 in unilateral
breast cancer; 0, ≥1 in bilateral breast cancer, breast and ovarian cancer, or ovarian cancer).
For the likelihood of pathologic profile, the breast cancers were categorized into luminal,
HER2, and basal-like type [38], combined with histologic grade (Bloom–Richardson grade),
and ovarian cancers were classified into two groups as carcinoma in situ/low grade
(grade 1) and high grade (grades 2 and 3). The LR of co-occurrence was analyzed using an
LR formulation introduced by the previous study [23]. To determine the prior probability,
we used in silico algorithms for missense or splicing variants using PRIORS (http://
hci-priors.hci.utah.edu/PRIORS/index.php (accessed on 23 March 2020)) [19] and indel
variants using CRAVAT (http://cravat.us/CRAVAT/ (accessed on 23 March 2020)) [39],
which included the variant effect scoring tool (VEST) indel algorithm [28].
4.4. Simulation Study Estimating the Number of Additional Samples Required to Resolve
Unclassified Status
We estimated how many samples were needed to reach ≥IARC 4 or ≤IARC 2 when
a BRCA1 or BRCA2 genetic variant was unclassified. For this, we created two benign
and pathogenic datasets, independent from the benign and pathogenic model groups.
Following recommendations by the previous study [20], a posterior probability of 0.049 or
less (IARC 2 or less) was regarded as a (likely) benign class, while a posterior probability of
0.95 or more (IARC 4 or more) was classified as a (likely) pathogenic class. The benign set
contained samples that had only (likely) benign variants, while the pathologic set contained
samples that had (likely) pathogenic variants in BRCA1/2.
Then, for each benign and pathologic set, we sampled LR scores of pathologic profiles
and personal/family cancer history independent from each other with replacement and
calculated the posterior probability with the assumption that there was no co-occurrence
with other pathologic variants. The calculation was repeated 1000 times for the different
prior probabilities [24] against increasing the number of patients, N (Supplementary Tables
S8–S11). Figure 2. shows the mean posterior probability of 1000 calculations against the
number of patients.
4.5. Analysis of BRCA1/2 PLPVs in the Korean BRCA
The BRCA1/2 PLPVs ((likely) pathogenic variants by 2015 ACMG/AMP or IARC 4/5
variants by prior our cohort analysis) were identified in gnomAD Korean (non-cancer,
v.2.1.1). We combined the data on BRCA1/2 PLPVs from our cohort and the Korean
general population (in gnomAD), and this was then referred to as the Korean BRCA.
The proportion of BRCA1/2 PLPVs found in every mutation bin was compared between
the Korean BRCA and a previous large-scale cohort (including various ethnicities in six
continents) [21] using interval likelihood ratios. Mutation bins across the span of the
coding DNA sequence of BRCA1 (30 mutation bins) or BRCA2 gene (19 mutation bins) were
defined by a previous study [21]. They were constructed using an algorithm in which each
mutation bin contained near-equal numbers of PLPVs, with bin length defined by distance
in base pairs. Mutationmapper (https://www.cbioportal.org/mutation_mapper (accessed
on 24 October 2020)) was used and modified to simultaneously visualize genetic lesions.
4.6. Estimation of Risks of Breast and Ovarian Cancers for BRCA1 and BRCA2 Carriers
A Bayesian calculation was applied to determine the risks of breast or ovarian cancer
in BRCA1 or BRCA2 PLPV carriers using the following formula [40,41]:
P(D|G) = P(G|D)P(D)
P(G
∣∣D)P(D) + P(G∣∣D)(1− P(D))
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In this formula, D = disease, G = genotype, D = absence of disease, P(D|G) = pene-
trance, P(G|D) = genotype frequency in cases, P
(
G
∣∣D) = genotype frequency in controls,
and P(D) = general population prevalence for breast or ovarian cancers. We defined the
frequency of disease (P(D)) as the cumulative risk of breast or ovarian cancers by age in
the Korean general population, based on analysis of the data from the annual report of
cancer statistics in Korea in 2016 (https://ncc.re.kr/main.ncc?uri=english/sub04_Statistics




used the BRCA1/2 PLPVs ((likely) pathogenic variants by 2015 ACMG/AMP or IARC 4/5
variants identified by prior our cohort analysis) in gnomAD Korean (non-cancer, v.2.1.1).
Due to insufficient epidemiologic information (e.g., age, sex) of participants in gnomAD,
we could not consider differences in P(G|D) by age or sex. The 95% confidence interval
(CI) for penetrance was calculated using binomial probability [40,41]. We considered the
risks of breast or ovarian cancer for BRCA1/2 carriers by mutation regions. For BRCA1, 5′
to c.2281 (region 1: breast cancer cluster regions, BCCR), c.2282 to c.4071 (region 2: ovarian
cancer cluster regions, OCCR), and c.4072 to 3′ (region 3: BCCR) were considered, while
BRCA2 considered 5′ to c.2830 (region 1: BCCR), c.2831 to c.6401 (region 2: OCCR), and
c.6402 to 3′ (region 3: BCCR) [21,22].
5. Conclusions
To date, large-scale studies related to BRCA1 or BRCA2 have focused on European
populations. Although we had limited data, we tried to identify the difference in the
spectrum of BRCA1 or BRCA2 variants and the related clinical outcomes between other
populations (mainly Europeans) and Koreans from various perspectives. Data from this
study reveal that BRCA 1 or BRCA2 variants in the non-European population is highly
specific; therefore, population-specific study is essential for clinical application of treatment
or prevention for breast or ovarian cancer.
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